Bradford J Shafer Insider Trading $TBPH Theravance Biopharma, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Bradford J Shafer.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Bradford J Shafer. Bradford J Shafer is Sr VP, Gen. Counsel, Secretary in Innoviva, Inc. ($THRX) and EVP, Gen. Counsel, Secretary in Theravance Biopharma, Inc. ($TBPH) and Sr VP, Gen. Counsel, Secretary in Theravance Biopharma, Inc. ($TBPH).
Bradford J Shafer in Theravance Biopharma, Inc.
Trading Symbol: TBPHIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Bradford J Shafer: EVP, Gen. Counsel, Secretary, Sr VP, Gen. Counsel, Secretary
Holdings: 282,138 shares
Current Value: $8,633,423
Latest Transaction: May 24 2021
$TBPH Market Capitalization: $1.64B
$TBPH Previous Close: $30.60
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Bradford J Shafer in Theravance Biopharma, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 24 2021 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 17.80 | 4,310 | 76,718 | 282,138 | 286.4 K to 282.1 K (-1.50 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 316,916 | 251.9 K to 316.9 K (+25.80 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 18.22 | 4,804 | 87,529 | 256,723 | 261.5 K to 256.7 K (-1.84 %) |
May 22 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 26.67 | 4,807 | 128,203 | 261,527 | 266.3 K to 261.5 K (-1.80 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 25.90 | 29,402 | 761,512 | 264,932 | 294.3 K to 264.9 K (-9.99 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 54,000 | 0 | 294,334 | 240.3 K to 294.3 K (+22.47 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 240,334 | 175.3 K to 240.3 K (+37.07 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 21.51 | 3,084 | 66,337 | 178,901 | 182 K to 178.9 K (-1.69 %) |
May 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 19.84 | 2,488 | 49,362 | 181,985 | 184.5 K to 182 K (-1.35 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.00 | 5,798 | 156,546 | 183,446 | 189.2 K to 183.4 K (-3.06 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 47,250 | 0 | 189,244 | 142 K to 189.2 K (+33.28 %) |
Feb 07 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 141,994 | 77 K to 142 K (+84.42 %) |
Nov 21 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 24.79 | 7,006 | 173,679 | 76,994 | 84 K to 77 K (-8.34 %) |
Aug 29 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.71 | 7,119 | 197,282 | 84,000 | 91.1 K to 84 K (-7.81 %) |
Aug 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 26.95 | 7,005 | 188,785 | 91,119 | 98.1 K to 91.1 K (-7.14 %) |
Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.85 | 25,355 | 706,182 | 98,124 | 123.5 K to 98.1 K (-20.53 %) |
Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.03 | 4,127 | 115,686 | 123,479 | 127.6 K to 123.5 K (-3.23 %) |
Aug 09 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.99 | 1,818 | 52,707 | 127,606 | 129.4 K to 127.6 K (-1.40 %) |
Jun 08 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 23.66 | 3,900 | 92,260 | 129,424 | 133.3 K to 129.4 K (-2.93 %) |
Jun 08 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 24.09 | 10,140 | 244,268 | 133,324 | 143.5 K to 133.3 K (-7.07 %) |
May 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 24.31 | 21,812 | 530,250 | 143,464 | 165.3 K to 143.5 K (-13.20 %) |
May 16 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 33,750 | 0 | 165,276 | 131.5 K to 165.3 K (+25.66 %) |
Feb 22 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 29.09 | 5,587 | 162,526 | 130,661 | 136.2 K to 130.7 K (-4.10 %) |
Feb 14 2018 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 9,000 | 0 | 136,248 | 127.2 K to 136.2 K (+7.07 %) |
Nov 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 28.58 | 7,079 | 202,318 | 127,248 | 134.3 K to 127.2 K (-5.27 %) |
Sep 08 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 30.77 | 14,670 | 451,350 | 134,327 | 149 K to 134.3 K (-9.85 %) |
Aug 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.40 | 7,079 | 193,965 | 148,997 | 156.1 K to 149 K (-4.54 %) |
May 23 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 36.83 | 7,079 | 260,720 | 156,076 | 163.2 K to 156.1 K (-4.34 %) |
Mar 07 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 31.86 | 26,829 | 854,772 | 161,453 | 188.3 K to 161.5 K (-14.25 %) |
Feb 22 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 33.78 | 12,440 | 420,223 | 188,282 | 200.7 K to 188.3 K (-6.20 %) |
Feb 08 2017 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 9,000 | 0 | 200,722 | 191.7 K to 200.7 K (+4.69 %) |
Nov 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 31.96 | 4,008 | 128,096 | 191,722 | 195.7 K to 191.7 K (-2.05 %) |
Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 27.16 | 37,078 | 1,007,038 | 195,730 | 232.8 K to 195.7 K (-15.93 %) |
Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 27.89 | 4,008 | 111,783 | 232,808 | 236.8 K to 232.8 K (-1.69 %) |
Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.14 | 4,870 | 137,042 | 236,816 | 241.7 K to 236.8 K (-2.02 %) |
Aug 22 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Sell | S | 28.55 | 7,174 | 204,818 | 241,686 | 248.9 K to 241.7 K (-2.88 %) |
May 24 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 20.55 | 4,008 | 82,364 | 248,860 | 252.9 K to 248.9 K (-1.59 %) |
Mar 17 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 115,000 | 0 | 251,165 | 136.2 K to 251.2 K (+84.46 %) |
Feb 23 2016 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 15.65 | 18,920 | 296,098 | 136,165 | 155.1 K to 136.2 K (-12.20 %) |
Nov 24 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 17.17 | 934 | 16,037 | 155,085 | 156 K to 155.1 K (-0.60 %) |
Aug 24 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 12.98 | 934 | 12,123 | 156,019 | 157 K to 156 K (-0.60 %) |
Jun 04 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 13.83 | 7,360 | 101,789 | 156,953 | 164.3 K to 157 K (-4.48 %) |
May 22 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 14.24 | 673 | 9,584 | 164,313 | 165 K to 164.3 K (-0.41 %) |
Feb 24 2015 | TBPH | Theravance Biophar ... | Shafer Bradford J | Sr VP, Gen. Counsel ... | Payment of Exercise | F | 19.52 | 674 | 13,156 | 163,088 | 163.8 K to 163.1 K (-0.41 %) |
Page: 1